1MacDonald RG, Henderson MA, Hirshfeld JW,et al. Patient-relatedvariables and restenosis after PTCA-report from the M-HEARTgroup. Am J Cardiol, 1990,66 (12) :926-931
2Sondergaard HM, Botker HE, Bottcher M, et al. Percutaneous coronary intervention in patients with diabetes mellitus. Ugeskr Laeger,2003,165 (2) :111-115
3Elezi S,Kastrati A,Pache J,et al. Diabetes mellitus and the clinicaland angiographic outcome after coronary stent placement. J Am CollCardiol, 1998,32(7): 1866-1873
4Kane GR,Patil CV,Sahoo PK,et al. Coronary stenting in diabetics:six months clinical and angiographic outcome. Indian Heart J,2000,52(4) :416-420
5Johansen O, Abdelnoor M, Brekke M, et al. Predictors of restenosisafter coronary angioplasty. A study on demographic and metabolicvariables. Scand Cardiovasc J,2001,35 (2) :86-91
6Otsuka M, Hayashi Y, Ueda H, et al. Predictive value of preprocedural fibrinogen concerning coronary stenting. Atherosclerosis,2002,164(2) :371-378
7Hong M, Kent K,Satler L,et al. Arc long term results different whenstents are used in de novo versus restenotic lesions? Circulation, 1996,94(1) :I-131
8Gruberg L, Hong MK, Mintz GS. Optimally deployed stents in thetreatment of restenotic versus de novo lesions. Am J Cardiol, 2000,85(3) :333-337
9Pratsos A,Fischman DL,Savage MP. et al. Restenosis in saphenousvein grafts. Curr Interv Cardiol Rep,2001,3 (4) :287-295
10Oliveri Z, Rubartelli P, Piscione F, et al. Immediate results andone-year clinical outcome after percutaneous coronary interventionin chronic total occlusions:data from a multicenter, prospective ,observational study (TOAST-GISE). J Am Coll Cardiol, 2003,
9Scheen AJ,Warzée F,Legrand VM.Drug-eluting stents:meta-analysis in diabetic patients[J].Eur Heart J,2004,25(23):2167-2168.
10Nishio K,Sakurai M,Kusuyama T,et al.A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes[J].Diabetes Care,2006,29(1):101-106.